New drug TAK-781 enters early safety testing for PSC
NCT ID NCT07229911
First seen Nov 17, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-stage study tests whether the drug TAK-781 is safe and tolerable. It first gives single or multiple doses to healthy volunteers, then a single dose to people with non-cirrhotic primary sclerosing cholangitis (PSC). The goal is to check for side effects and how the body processes the drug, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.